The IBN SINA Pharmaceutical Industry PLC

DSE:IBNSINA Stock Report

Market Cap: ৳9.0b

IBN SINA Pharmaceutical Industry Past Earnings Performance

Past criteria checks 2/6

IBN SINA Pharmaceutical Industry has been growing earnings at an average annual rate of 12.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 13.8% per year. IBN SINA Pharmaceutical Industry's return on equity is 16.4%, and it has net margins of 5.3%.

Key information

12.5%

Earnings growth rate

12.5%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate13.8%
Return on equity16.4%
Net Margin5.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How IBN SINA Pharmaceutical Industry makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DSE:IBNSINA Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411,2315923,6140
30 Jun 2411,3716713,6170
31 Mar 2410,8666903,4850
31 Dec 2310,3356483,4080
30 Sep 239,5666243,2000
30 Jun 239,1256053,0510
31 Mar 238,7126142,8790
31 Dec 228,5686072,8270
30 Sep 228,5706092,7870
30 Jun 228,4806062,7450
31 Mar 228,3845622,6940
31 Dec 218,2965632,6530
30 Sep 218,0155292,5690
30 Jun 217,3764892,3680
31 Mar 216,9864332,2560
31 Dec 206,7304192,1650
30 Sep 206,3844052,0540
30 Jun 206,1923931,9970
31 Mar 206,0513891,9210
31 Dec 195,7613781,8240
30 Sep 195,4733501,7390
30 Jun 195,2643361,6730
31 Mar 194,9784831,5900
31 Dec 184,7594691,5140
30 Sep 184,7474671,5170
30 Jun 184,6574521,4870
31 Mar 184,5432671,4480
31 Dec 174,5002581,4330
30 Sep 174,3122521,3760
30 Jun 174,0092341,2820
31 Mar 173,9512241,2650
31 Dec 163,7812241,2130
30 Sep 163,6892211,1860
30 Jun 163,4912031,1200
31 Mar 163,2941931,0510
31 Dec 153,1631781,0460
30 Sep 152,9311479790
30 Jun 152,9221459850
31 Mar 152,8151369620
31 Dec 142,6791278880
30 Sep 142,6091028820
30 Jun 142,454998270
31 Mar 142,305907830
31 Dec 132,209877440

Quality Earnings: IBNSINA has high quality earnings.

Growing Profit Margin: IBNSINA's current net profit margins (5.3%) are lower than last year (6.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IBNSINA's earnings have grown by 12.5% per year over the past 5 years.

Accelerating Growth: IBNSINA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IBNSINA had negative earnings growth (-5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-5.5%).

Return on Equity

High ROE: IBNSINA's Return on Equity (16.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:20
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

The IBN SINA Pharmaceutical Industry PLC is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tanay RoyIDLC Securities Limited